Is erlotinib a monoclonal antibody?
Dual targeting of EGFR using one monoclonal antibody (mAb; cetuximab or panitumumab) and one tyrosine kinase inhibitor (EGFR-TKI; gefitinib or erlotinib) is a potential therapeutic approach.
What type of inhibitor is erlotinib?
Erlotinib is a tyrosine kinase inhibitor (TKI) which is a type of cancer growth blocker. It blocks proteins on cancer cells that encourage the cancer to grow. These proteins are called epidermal growth factor receptors (EGFR).
Where does erlotinib bind?
Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain.
How does erlotinib inhibit EGFR?
Erlotinib (Tarceva) belongs to a class of drugs known as tyrosine kinase inhibitors. It works by blocking the function of a protein called the epidermal growth factor receptor (EGFR). The EGFR is found on the surface of many cancer cells as well as normal cells.
Which is better EGFR TKI followed by Osimertinib between afatinib and gefitinib erlotinib?
Conclusions: Afatinib followed by osimertinib may provide better clinical benefit for NSCLC patients harboring T790M mutation compared with 1st-G EGFR TKIs. Afatinib followed by osimertinib is one of the first line sequential options even if osimertinib can be used as a first line therapy.
What is vincristine and vinblastine?
Vinblastine and vincristine (vinca alkaloids), derived from the periwinkle plant, along with etoposide, act primarily to stop spindle formation within the dividing cell during DNA replication and cell division. These drugs are important agents in the treatment of leukemias, lymphomas, and testicular cancer.
What is the difference between vincristine and vinblastine?
Vinblastine is used to treat Hodgkin’s disease (a form of lymphoid cancer), while vincristine is used clinically in the treatment of children’s leukaemia.
Is cetuximab chemotherapy or immunotherapy?
Immunotherapy with monoclonal antibodies, such as avelumab and cetuximab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Are erlotinib and sunitinib synergistic in the treatment of NSCLC xenograft mice?
Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice The experimental data and modeling confirm synergistic anticancer effect of ER and SU in the treatment of A549 xenograft mice.
What is the A549 model of lung cancer?
The A549 CDX model is the highly utilized xenograft lung cancer model for studying standard of care and novel therapeutics (i.e. erlotinib, gefitinib, lapatinib, paclitaxel) due to overexpression of EGFR and HER-2. Download Altogen Labs A549 Xenograft Model PowerPoint Presentation:
What is the origin of A549 cells?
The A549 hypotriploid epithelial cell line was derived from skin cells of a 58-year-old Caucasian male with pulmonary adenocarcinoma in 1972 by D. J. Giard. The A549 cell line is an excellent host for studies of lung cancer as well human infections related to the lungs.
What is the A549 mouse used for?
The A549 subcutaneous CDX mouse model is commonly used in preclinical tumor growth delay studies, including lapatinib as a monotherapy (reduction in angiogenesis), or combination therapies of erlotinib and gefitinib (EGFR-targeted agents).